|
DK2352763T4
(da)
*
|
2008-10-01 |
2022-10-17 |
Amgen Res Munich Gmbh |
Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
|
|
ME03008B
(me)
*
|
2011-09-19 |
2018-10-20 |
Axon Neuroscience Se |
Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
EP2906596B1
(en)
*
|
2012-10-12 |
2023-12-27 |
Arizona Board of Regents on behalf of Arizona State University |
Antibody based reagents that specifically recognize toxic oligomeric forms of tau
|
|
US10501531B2
(en)
|
2013-03-13 |
2019-12-10 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
AU2014368696A1
(en)
*
|
2013-12-20 |
2016-06-02 |
F. Hoffmann-La Roche Ag |
Humanized anti-Tau(pS422) antibodies and methods of use
|
|
EP3083696B1
(en)
*
|
2013-12-20 |
2018-02-14 |
F.Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
LT3099713T
(lt)
*
|
2014-02-02 |
2020-07-10 |
Medimmune Limited |
Chimerinis baltymas, sudarytas iš ngf antagonistinio domeno ir tnfa antagonistinio domeno
|
|
SG10201902850TA
(en)
|
2014-09-30 |
2019-04-29 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
NZ775762A
(en)
|
2015-06-05 |
2025-02-28 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
WO2016207245A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
|
AU2016283344B2
(en)
|
2015-06-24 |
2022-08-04 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion protein containing BDNF
|
|
EA039366B1
(ru)
*
|
2015-06-24 |
2022-01-19 |
Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. |
Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
|
|
US10344081B2
(en)
|
2015-07-06 |
2019-07-09 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
WO2017005734A1
(en)
|
2015-07-06 |
2017-01-12 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
WO2017027691A1
(en)
*
|
2015-08-13 |
2017-02-16 |
New York University |
Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
|
WO2017176835A2
(en)
*
|
2016-04-06 |
2017-10-12 |
Imago Pharmaceuticals, Inc. |
Therapeutic antibodies for treatment of neurodegeneration
|
|
MY198194A
(en)
|
2016-05-02 |
2023-08-09 |
Prothena Biosciences Ltd |
Antibodies Recognizing Tau
|
|
MX2018013386A
(es)
|
2016-05-02 |
2019-02-28 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau.
|
|
PT3452507T
(pt)
|
2016-05-02 |
2022-12-20 |
Prothena Biosciences Ltd |
Imunoterapia anti-tau
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
CA3030754C
(en)
*
|
2016-07-20 |
2022-04-26 |
Anahit Ghochikyan |
Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
|
|
WO2018018031A1
(en)
*
|
2016-07-22 |
2018-01-25 |
New York University |
Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
|
|
UA128383C2
(uk)
|
2016-12-07 |
2024-07-03 |
Дженентек, Інк. |
Антитіло до тау-білка та спосіб його застосування
|
|
MX2019006330A
(es)
|
2016-12-07 |
2019-09-26 |
Genentech Inc |
Anticuerpos anti-tau y metodos de uso.
|
|
RU2768404C2
(ru)
*
|
2016-12-23 |
2022-03-24 |
Ремд Биотерапьютикс, Инк. |
Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
|
|
CA3052936A1
(en)
|
2016-12-26 |
2018-07-05 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion protein of bdnf and anti-transferrin receptor antibody
|
|
KR102497564B1
(ko)
|
2016-12-26 |
2023-02-07 |
제이씨알 파마 가부시키가이샤 |
혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
|
|
BR112019013953A2
(pt)
*
|
2017-01-06 |
2020-02-11 |
Abl Bio Inc. |
Anticorpo anti-a-syn e uso do mesmo
|
|
MX2019008827A
(es)
*
|
2017-01-30 |
2019-09-26 |
Alexion Pharma Inc |
Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
|
|
AU2018217720A1
(en)
*
|
2017-02-10 |
2019-09-05 |
The Trustees Of The University Of Pennsylvania |
Anti-factor D antibodies and uses thereof
|
|
JP7364221B2
(ja)
*
|
2017-03-06 |
2023-10-18 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
抗ｃ５抗体およびその使用
|
|
SG11201908744PA
(en)
*
|
2017-03-23 |
2019-10-30 |
Univ Pennsylvania |
Anti-c5a antibodies and uses thereof
|
|
EP3601346A1
(en)
*
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
WO2018199176A1
(en)
*
|
2017-04-26 |
2018-11-01 |
Mitsubishi Tanabe Pharma Corporation |
Syndecan-1 (cd138) binding agents and uses thereof
|
|
KR102784294B1
(ko)
|
2017-05-02 |
2025-03-19 |
프로테나 바이오사이언시즈 리미티드 |
타우 인식 항체
|
|
WO2018218352A1
(en)
*
|
2017-05-30 |
2018-12-06 |
The University Of British Columbia |
Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto
|
|
EP3431496A1
(en)
*
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti- isoasp7 amyloid beta antibodies and uses thereof
|
|
CN111201030B
(zh)
|
2017-07-25 |
2024-11-01 |
真和制药有限公司 |
通过阻断tim-3和其配体的相互作用治疗癌症
|
|
EP3661961A4
(en)
*
|
2017-08-02 |
2021-04-14 |
Stressmarq Biosciences Inc. |
ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
|
|
WO2019074124A1
(en)
*
|
2017-10-12 |
2019-04-18 |
Keio University |
MONOCLONAL ANTI-AQP3 ANTIBODY BINDING SPECIFICALLY TO THE EXTRACELLULAR DOMAIN OF AQUAPORIN 3 (AQP3) AND USE THEREOF
|
|
CN112040970A
(zh)
*
|
2017-11-29 |
2020-12-04 |
得克萨斯大学体系董事会 |
用于癌症疗法的组合物和方法
|
|
AU2018379306A1
(en)
*
|
2017-12-05 |
2020-06-25 |
Mabion Sa |
Combination therapy of multiple sclerosis comprising a CD20 ligand
|
|
EP3725806A4
(en)
|
2017-12-14 |
2022-03-30 |
ABL Bio Inc. |
BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
|
|
WO2019113711A1
(en)
|
2017-12-14 |
2019-06-20 |
University Of Ottawa |
Exosome packaging and targeted autophagy
|
|
WO2019118906A2
(en)
*
|
2017-12-14 |
2019-06-20 |
University Of Florida Research Foundation |
Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
|
|
US11773171B2
(en)
|
2017-12-19 |
2023-10-03 |
Surrozen Operating, Inc. |
WNT surrogate molecules and uses thereof
|
|
CN111699003B
(zh)
*
|
2017-12-19 |
2024-05-03 |
瑟罗泽恩奥普瑞汀公司 |
抗lrp5/6抗体和使用方法
|
|
JP7490565B2
(ja)
|
2017-12-29 |
2024-05-27 |
アレクトル エルエルシー |
抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
|
|
AU2019205090A1
(en)
*
|
2018-01-05 |
2020-08-06 |
Ac Immune Sa |
Misfolded TDP-43 binding molecules
|
|
KR102850216B1
(ko)
*
|
2018-01-29 |
2025-08-26 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Tlr2-매개 질환 및 장애를 치료하기 위한 요법 및 방법
|
|
WO2019152706A1
(en)
|
2018-01-31 |
2019-08-08 |
Alector Llc |
Anti-ms4a6a antibodies and methods of use thereof
|
|
US11472874B2
(en)
|
2018-01-31 |
2022-10-18 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
|
AU2019215202B2
(en)
*
|
2018-02-01 |
2025-11-13 |
Memorial Sloan Kettering Cancer Center |
Antibodies to Galectin-3 and methods of use thereof
|
|
US12398201B2
(en)
*
|
2018-02-19 |
2025-08-26 |
New York University |
Tau single domain antibodies
|
|
WO2019165156A1
(en)
|
2018-02-23 |
2019-08-29 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Cd83-binding chimeric antigen receptors
|
|
BR112020016738A2
(pt)
|
2018-03-14 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
|
|
TWI791794B
(zh)
*
|
2018-03-20 |
2023-02-11 |
瑞士商諾華公司 |
藥物組合
|
|
MX2020010653A
(es)
|
2018-04-09 |
2020-10-28 |
Origincell Therapeutics Co Ltd |
Anticuerpo anti-muerte programada-ligando 1 y su uso.
|
|
JP2021520854A
(ja)
*
|
2018-04-11 |
2021-08-26 |
タイチャン ピーティーイー．リミテッドＴｙｃｈａｎ Ｐｔｅ．Ｌｔｄ． |
黄熱を処置するための方法および組成物
|
|
EP3773739A1
(en)
*
|
2018-04-12 |
2021-02-17 |
MediaPharma S.r.l. |
Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
|
|
WO2019207513A1
(en)
*
|
2018-04-24 |
2019-10-31 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
|
|
US20210054079A1
(en)
*
|
2018-04-25 |
2021-02-25 |
Medimmune Limited |
Formulations of human anti-pd-li antibodies
|
|
US12162952B2
(en)
|
2018-04-27 |
2024-12-10 |
Neurimmune Ag |
Human-derived anti-(poly-GA) dipeptide repeat (DPR) antibody
|
|
GB201806918D0
(en)
*
|
2018-04-27 |
2018-06-13 |
Enleofen Bio Pte Ltd |
Combination treatment for eye fibrosis
|
|
US11613571B2
(en)
*
|
2018-05-23 |
2023-03-28 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions comprising antibody variants
|
|
WO2019225787A1
(ko)
*
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
WO2019229296A1
(en)
*
|
2018-05-29 |
2019-12-05 |
Teknologian Tutkimuskeskus Vtt Oy |
Anti-thyroid hormone (t4) recombinant antibody or antigen binding fragment
|
|
WO2019229155A1
(en)
*
|
2018-05-31 |
2019-12-05 |
Glenmark Pharmceuticals S.A. |
Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
TW202012444A
(zh)
*
|
2018-06-14 |
2020-04-01 |
美商貝斯以色列女執事醫療中心有限公司 |
用於通過外核苷酸酶抑制及抗體介導型靶標細胞攝入來預防或逆轉t 細胞耗竭之組合物及方法
|
|
WO2020010024A1
(en)
*
|
2018-07-02 |
2020-01-09 |
Abcentra, Llc |
Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
PT3820569T
(pt)
|
2018-07-12 |
2025-01-14 |
Invox Pharma Ltd |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
ES3044118T3
(en)
*
|
2018-07-12 |
2025-11-26 |
Invox Pharma Ltd |
Antibody molecules that bind cd137 and ox40
|
|
CN110713537B
(zh)
*
|
2018-07-13 |
2023-04-21 |
江苏怀瑜药业有限公司 |
一种sema4d抗体及其制备方法和应用
|
|
CN112513078B
(zh)
*
|
2018-07-31 |
2022-11-18 |
沈为群 |
抗il-17a抗体及其用途
|
|
WO2020033646A1
(en)
*
|
2018-08-08 |
2020-02-13 |
Orionis Biosciences, Inc. |
SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
|
|
CA3109999A1
(en)
*
|
2018-08-21 |
2020-02-27 |
Abl Bio Inc. |
Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
|
|
JP7653909B2
(ja)
|
2018-09-06 |
2025-03-31 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
ヒト化抗ｃ５抗体とその利用
|
|
CN111253485A
(zh)
*
|
2018-11-30 |
2020-06-09 |
上海开拓者生物医药有限公司 |
抗人tim-3单克隆抗体及其应用
|
|
CN113286825B
(zh)
*
|
2018-11-30 |
2024-06-18 |
爱必乐生物公司 |
抗pd-l1/抗4-1bb双特异性抗体及其用途
|
|
JP6892180B2
(ja)
*
|
2018-12-03 |
2021-06-23 |
株式会社ｍＡｂＰｒｏｔｅｉｎ |
活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用
|
|
JP2022512161A
(ja)
*
|
2018-12-11 |
2022-02-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
免疫療法のための組成物及び方法
|
|
TWI734279B
(zh)
*
|
2018-12-14 |
2021-07-21 |
美商美國禮來大藥廠 |
抗α-突觸核蛋白抗體及其用途
|
|
WO2020160156A2
(en)
|
2019-01-30 |
2020-08-06 |
Immutics, Inc. |
Anti-gal3 antibodies and uses thereof
|
|
CA3129501A1
(en)
*
|
2019-02-15 |
2020-08-20 |
University Of Southern California |
Lym-1 and lym-2 antibody compositions and improved car constructs
|
|
MA54955A
(fr)
*
|
2019-02-15 |
2021-12-22 |
Integral Molecular Inc |
Anticorps anti-claudine 6 et leurs utilisations
|
|
JP2022520632A
(ja)
|
2019-02-15 |
2022-03-31 |
インテグラル・モレキュラー・インコーポレイテッド |
共通軽鎖を含む抗体及びその使用
|
|
JP7630834B2
(ja)
|
2019-03-03 |
2025-02-18 |
プロセナ バイオサイエンシーズ リミテッド |
タウ認識抗体
|
|
EP3947445A1
(en)
*
|
2019-04-04 |
2022-02-09 |
Vanderbilt University |
Hiv/hcv cross-reactive antibodies and uses thereof
|
|
JP2022530063A
(ja)
*
|
2019-04-24 |
2022-06-27 |
ヤンセン バイオテツク，インコーポレーテツド |
抗体製剤
|
|
TWI875757B
(zh)
*
|
2019-05-08 |
2025-03-11 |
瑞士商諾華公司 |
T1dm和胰島炎治療中使用之抗cd40抗體
|
|
TW202110878A
(zh)
*
|
2019-05-16 |
2021-03-16 |
法商賽諾菲公司 |
在神經系統中表現抗原結合蛋白
|
|
EP3971208A4
(en)
*
|
2019-05-16 |
2022-11-30 |
Qilu Pharmaceutical Co., Ltd. |
ANTIBODIES TO CLAUDIN 18A2 AND USE THEREOF
|
|
AU2020289301B2
(en)
*
|
2019-06-04 |
2025-07-24 |
Biotheus Inc. |
CEACAM5-resistant monoclonal antibody and preparation method thereof and use thereof
|
|
MX2021015473A
(es)
*
|
2019-06-13 |
2022-04-20 |
Prestige Biopharma Pte Ltd |
Nuevo anticuerpo específico para cthrc1 y su uso.
|
|
FR3099160B1
(fr)
*
|
2019-07-23 |
2022-05-06 |
Univ Grenoble Alpes |
Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
|
|
ES3059248T3
(en)
*
|
2019-07-26 |
2026-03-19 |
Sinocelltech Ltd |
Humanized anti-il17a antibody and use thereof
|
|
CA3145885A1
(en)
*
|
2019-07-31 |
2021-02-04 |
Jeonghoon Sun |
Anti-ms4a4a antibodies and methods of use thereof
|
|
AU2020334893A1
(en)
*
|
2019-08-16 |
2022-02-24 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Chimeric antigen receptors for treating myeloid malignancies
|
|
CN114430747B
(zh)
*
|
2019-09-26 |
2025-02-25 |
豪夫迈·罗氏有限公司 |
抗csf-1r抗体
|
|
EP4041757A4
(en)
*
|
2019-09-26 |
2024-04-17 |
Regents of the University of Minnesota |
VIRAL ANTIGEN BINDING NK ENGAGERS COMPOUNDS AND METHODS OF USE
|
|
EP4034569A4
(en)
*
|
2019-09-26 |
2023-11-01 |
Wuxi Biologics Ireland Limited |
NOVEL BISPECIFIC ANTI-PD-L1/ANTI-LAG-3 ANTIBODY AND ITS USES
|
|
EP4037699A1
(en)
*
|
2019-09-30 |
2022-08-10 |
SciRhom GmbH |
Protein binders to irhom2 epitopes
|
|
WO2021071830A1
(en)
|
2019-10-07 |
2021-04-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
IL292442A
(en)
*
|
2019-11-04 |
2022-06-01 |
Medimmune Ltd |
Anti-il-33 therapeutic agent for the treatment of kidney disorders
|
|
JP6761889B1
(ja)
*
|
2019-11-11 |
2020-09-30 |
株式会社Ｇｓｐエンタープライズ |
抗ヒトＣｒｉｐｔｏ−１抗体
|
|
US20220275103A1
(en)
*
|
2019-11-18 |
2022-09-01 |
CentricsBio, Inc. |
Anti-cd300c monoclonal antibody and biomarker thereof for preventing or treating cancer
|
|
CA3159050A1
(en)
*
|
2019-11-21 |
2021-05-27 |
Jack A. Elias |
Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells
|
|
IL293613A
(en)
*
|
2019-12-06 |
2022-08-01 |
Univ Antwerpen |
Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
|
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
|
BR112022013892A2
(pt)
*
|
2020-01-13 |
2022-10-04 |
Truebinding Inc |
Anticorpos anti-gal3 e métodos de uso
|
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
BR112022014417A2
(pt)
*
|
2020-01-24 |
2022-09-13 |
Pfizer |
Anticorpos anti-e-selectina, composições e métodos de uso
|
|
US20230080224A1
(en)
*
|
2020-02-07 |
2023-03-16 |
Agency For Science, Technology And Research |
Antigen-binding molecules against alppl2 and/or alpp and uses thereof
|
|
MX2022009476A
(es)
*
|
2020-02-10 |
2022-08-22 |
Regeneron Pharma |
Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
|
|
JP2023514972A
(ja)
*
|
2020-02-12 |
2023-04-12 |
ザ スクリプス リサーチ インスティテュート |
長時間作用型ｇｍ－ｃｓｆおよび使用方法
|
|
WO2021162394A1
(ko)
*
|
2020-02-14 |
2021-08-19 |
충북대학교 산학협력단 |
B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
|
|
GB202003632D0
(en)
*
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
|
WO2021200840A1
(ja)
*
|
2020-03-30 |
2021-10-07 |
国立研究開発法人医薬基盤・健康・栄養研究所 |
エピトープ領域架橋型バイパラトピック抗体、及びそれを製造する方法
|
|
KR20250107297A
(ko)
|
2020-04-02 |
2025-07-11 |
리제너론 파아마슈티컬스, 인크. |
항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
|
|
KR102485892B1
(ko)
*
|
2020-04-09 |
2023-01-09 |
주식회사 에이프릴바이오 |
고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
|
|
WO2021222168A2
(en)
*
|
2020-04-28 |
2021-11-04 |
Sola Biosciences Llc |
Compositions and methods for the treatment of tdp-43 proteinopathies
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP4157338A4
(en)
|
2020-05-26 |
2024-11-13 |
TrueBinding, Inc. |
METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
|
|
MX2022014734A
(es)
*
|
2020-05-26 |
2023-03-15 |
Regeneron Pharma |
Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.
|
|
WO2021243204A1
(en)
*
|
2020-05-29 |
2021-12-02 |
23Andme, Inc. |
Anti-cd200r1 antibodies and methods of use thereof
|
|
US20230227567A1
(en)
*
|
2020-06-04 |
2023-07-20 |
Selvax Pty Ltd |
Agonist anti-cd40 antibodies
|
|
WO2021252519A1
(en)
*
|
2020-06-08 |
2021-12-16 |
University Of Florida Research Foundation, Inc. |
Materials and methods for the diagnosis and treatment of cancer
|
|
EP4168452A4
(en)
*
|
2020-06-18 |
2024-07-10 |
BioAtla, Inc. |
Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
IL299865A
(en)
*
|
2020-07-16 |
2023-03-01 |
Nanjing Legend Biotech Co Ltd |
Multispecific chimeric antigen receptors and uses thereof
|
|
IL299867A
(en)
*
|
2020-07-16 |
2023-03-01 |
Nanjing Legend Biotech Co Ltd |
Cd19 binding molecules and uses thereof
|
|
BR112022026999A2
(pt)
|
2020-07-17 |
2023-01-24 |
Boehringer Ingelheim Int |
Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
|
|
JP2023537470A
(ja)
*
|
2020-08-03 |
2023-09-01 |
ヤンセン バイオテツク，インコーポレーテツド |
ウイルス治療における多方向バイオ輸送のための材料及び方法
|
|
US20230265176A1
(en)
*
|
2020-08-14 |
2023-08-24 |
Chugai Seiyaku Kabushiki Kaisha |
One-armed antigen-binding molecules and uses thereof
|
|
JP7634082B2
(ja)
*
|
2020-08-18 |
2025-02-20 |
オメロス コーポレーション |
補体因子ｄを検出するためのモノクローナル抗体、組成物、および方法
|
|
JP2023538071A
(ja)
*
|
2020-08-20 |
2023-09-06 |
アンブルックス，インコーポレイテッド |
抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
|
|
EP4209509A4
(en)
*
|
2020-09-03 |
2025-03-19 |
Harbour Biomed (Shanghai) Co., Ltd |
ROR1-TARGETTING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION THEREOF AND USE THEREOF
|
|
WO2022056197A1
(en)
*
|
2020-09-11 |
2022-03-17 |
Janssen Biotech, Inc. |
Immune targeting molecules and uses thereof
|
|
CN116648463A
(zh)
*
|
2020-09-18 |
2023-08-25 |
伊克诺斯科学公司 |
Cd47-cd38双特异性抗体
|
|
MX2023003214A
(es)
|
2020-09-18 |
2023-05-24 |
Regeneron Pharma |
Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.
|
|
EP4223775A4
(en)
*
|
2020-09-29 |
2025-07-30 |
Kunming Sinoway Natural Pharmaceuticals Co Ltd |
HUMANIZED RECOMBINANT ANTI-CD22 IMMUNOTOXIN AND ITS APPLICATION
|
|
KR20230104611A
(ko)
*
|
2020-09-30 |
2023-07-10 |
드렌 바이오, 인크. |
항-cd94 항체 및 이의 사용 방법
|
|
US20240018231A1
(en)
*
|
2020-10-30 |
2024-01-18 |
Rush University Medical Center |
Intranasal immunotherapt for the treatment of alzheimer's disease
|
|
CN114456268B
(zh)
*
|
2020-11-09 |
2023-08-18 |
江苏中新医药有限公司 |
抗胞外-5’-核苷酸酶的抗体序列
|
|
CN114470189B
(zh)
*
|
2020-11-12 |
2024-01-16 |
达石药业(广东)有限公司 |
Ngf抗体在cipn性疼痛中的应用
|
|
MX2023007133A
(es)
*
|
2020-12-17 |
2023-06-27 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos.
|
|
US12325752B2
(en)
*
|
2020-12-18 |
2025-06-10 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to NPR1 agonists
|
|
CN116917491A
(zh)
*
|
2020-12-18 |
2023-10-20 |
Ac免疫有限公司 |
抗体递送
|
|
JP2024505390A
(ja)
*
|
2021-01-08 |
2024-02-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
第ｘｉａ因子阻害剤としての抗体および抗原結合ペプチド、およびその使用
|
|
US20250277031A1
(en)
*
|
2021-01-08 |
2025-09-04 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Antibody specifically binding to cd47 and antigen-binding fragment thereof
|
|
CA3209006A1
(en)
*
|
2021-03-04 |
2022-09-09 |
Boehringer Ingelheim International Gmbh |
Methods for the treatment of gpp
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
EP4305065A1
(en)
*
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
IL305690B2
(en)
*
|
2021-03-18 |
2025-10-01 |
Medimmune Ltd |
A therapeutic binding molecule that binds to CCR9
|
|
JP7714675B2
(ja)
*
|
2021-03-24 |
2025-07-29 |
ヤンセン バイオテツク，インコーポレーテツド |
ＣＤ７９ｂ、ＣＤ２０、及びＣＤ３を標的とする三重特異性抗体
|
|
IL305600A
(en)
*
|
2021-03-31 |
2023-11-01 |
Incyte Corp |
Multispecific binding regions containing novel PD-1 binding regions
|
|
KR20230163503A
(ko)
*
|
2021-03-31 |
2023-11-30 |
메뤼스 엔.페. |
신규한 pd-1 결합 도메인
|
|
KR20230166090A
(ko)
*
|
2021-04-06 |
2023-12-06 |
테네오바이오, 인코포레이티드 |
항-cd19 항체 및 car-t 구조체
|
|
CN115260312B
(zh)
*
|
2021-04-30 |
2025-02-14 |
保诺科技（北京）有限公司 |
结合ox40的抗体或抗原结合片段
|
|
US12201857B2
(en)
*
|
2021-06-22 |
2025-01-21 |
Twist Bioscience Corporation |
Methods and compositions relating to covid antibody epitopes
|
|
TWI879694B
(zh)
*
|
2021-06-25 |
2025-04-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
|
AR126220A1
(es)
*
|
2021-06-25 |
2023-09-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
|
US12448451B2
(en)
*
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
US12496470B2
(en)
*
|
2021-07-14 |
2025-12-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
US11542340B1
(en)
*
|
2021-10-29 |
2023-01-03 |
Biodesix, Inc. |
Antibodies targeting pulmonary nodule specific biomarkers and uses thereof
|
|
JP2024542823A
(ja)
|
2021-12-06 |
2024-11-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
アンタゴニスト抗ｎｐｒ１抗体およびその使用方法
|
|
TW202430574A
(zh)
|
2022-11-30 |
2024-08-01 |
美商積分分子股份有限公司 |
針對密連蛋白６之抗體，包括其雙特異性格式
|
|
EP4602067A1
(en)
*
|
2023-01-20 |
2025-08-20 |
Mabwell Therapeutics Inc. |
Anti-amyloid beta protofibril/oligomer antibodies and uses thereof
|
|
US20240285789A1
(en)
*
|
2023-02-23 |
2024-08-29 |
University Of Utah Research Foundation |
Compositions and Methods for Killing PD-1 Positive Cells
|
|
KR20250173600A
(ko)
|
2023-03-17 |
2025-12-10 |
옥시토프 파마 비.브이. |
항-포스포콜린 항체 및 그 사용 방법
|
|
WO2025257181A1
(en)
*
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|